Clinicians’ Feedback on Patient/Carer Experience After Switching of Growth Hormone Treatment in Pediatric Patients During COVID-19

References

• Kremidas D, Wisniewski T, Divino VM, et al. Administration burden associated with recombinant human growth hormone treatment: perspectives of patients and caregivers. J Pediatr Nurs. 2013;28(1):55–63. doi:10.1016/j.pedn.2011.12.006
   PubMed Web of Science ®Google Scholar
• Meinhardt U, Eiholzer U, Seitz L, Bøgelund M, Kappelgaard AM. Parent preference in Switzerland for easy-to-use attributes of growth hormone injection devices quantified by willingness to pay. Expert Rev Med Devices. 2014;11(1):31–38. doi:10.1586/17434440.2014.856754
   PubMed Web of Science ®Google Scholar
• Fisher BG, Acerini CL. Understanding the growth hormone therapy adherence paradigm: a systematic review. Horm Res Paediatr. 2013;79(4):189–196. doi:10.1159/000350251
   PubMed Web of Science ®Google Scholar
• Collett-Solberg PF, Ambler G, Backeljauw PF, et al. Diagnosis, genetics, and therapy of short stature in children: a growth hormone research society international perspective. Horm Res Paediatr. 2019;92(1):1–14. doi:10.1159/000502231
   PubMed Web of Science ®Google Scholar
• Wilson TA, Rose SR, Cohen P, et al. Update of guidelines for the use of growth hormone in children: the Lawson Wilkins pediatric endocrinology society drug and therapeutics committee. J Pediatr. 2003;143(4):415–421. doi:10.1067/S0022-3476(03)00246-4
   PubMed Web of Science ®Google Scholar
• Rohrer TR, Horikawa R, Kappelgaard AM. Growth hormone delivery devices: current features and potential for enhanced treatment adherence. Expert Opin Drug Deliv. 2017;14(11):1253–1264. doi:10.1080/17425247.2017.1243526
   PubMed Web of Science ®Google Scholar
• Prader-Willi Syndrome Association. Latest update on the genotropin mini quick shortage from Pfizer Pharmaceuticals; 2020. Available from: https://www.pwsausa.org/latest-update-on-the-genotropin-mini-quick-shortage-from-pfizer-pharmaceuticals/. Accessed May, 2021.
   Google Scholar
• Webster P. Virtual health care in the era of COVID-19. Lancet. 2020;395(10231):1180–1181. doi:10.1016/S0140-6736(20)30818-7
   PubMed Web of Science ®Google Scholar
• Glazier RH, Green ME, Wu FC, Frymire E, Kopp A, Kiran T. Shifts in office and virtual primary care during the early COVID-19 pandemic in Ontario, Canada. CMAJ. 2021;193(6):E200–e210. doi:10.1503/cmaj.202303
   Google Scholar
• AIFA Italian Medicines Agency. Note 39. Drug note: somatropin; 2021. Available from: https://www.aifa.gov.it/en/nota-39. Accessed May, 2021.
   Google Scholar
• Sävendahl L, Polak M, Backeljauw P, et al. Treatment of children with GH in the United States and Europe: long-term follow-up from NordiNet® IOS and ANSWER program. J Clin Endocrinol Metab. 2019;104(10):4730–4742. doi:10.1210/jc.2019-00775
   PubMed Web of Science ®Google Scholar
• Sävendahl L, Polak M, Backeljauw P, et al. Long-term safety of growth hormone treatment in childhood: two large observational studies NordiNet ® IOS and ANSWER. J Clin Endocrinol Metab. 2021;106(6):1728–1741. doi:10.1210/clinem/dgab080
   PubMed Web of Science ®Google Scholar
• Tauber M, Jaquet D, Jesuran-Perelroizen M, Petrus M, Bertrand AM, Coutant R. User assessment of Norditropin NordiFlex(®), a new prefilled growth hormone pen: a Phase IV multicenter prospective study. Patient Prefer Adherence. 2013;7:455–462. doi:10.2147/PPA.S43460
   PubMed Web of Science ®Google Scholar
• Stanhope R, Buchanan C, Butler G, et al. An open-label acceptability study of Norditropin SimpleXx–a new liquid growth hormone formulation. J Pediatr Endocrinol Metab. 2001;14(6):735–740. doi:10.1515/JPEM.2001.14.6.735
   PubMed Web of Science ®Google Scholar
• Rohrer TR, Winter F, Qvist M, Kappelgaard AM. Comparison of intuitiveness, ease of use and preference among three prefilled, disposable growth hormone injection pens. Expert Opin Drug Deliv. 2013;10(12):1603–1612. doi:10.1517/17425247.2013.829451
   PubMed Web of Science ®Google Scholar
• Pfützner A, Hartmann K, Winter F, Fuchs GS, Kappelgaard AM, Rohrer TR. Intuitiveness, ease of use, and preference of a prefilled growth hormone injection pen: a noninterventional, randomized, open-label, crossover, comparative usability study of three delivery devices in growth hormone-treated pediatric patients. Clin Ther. 2010;32(11):1918–1934. doi:10.1016/j.clinthera.2010.10.010
   PubMed Web of Science ®Google Scholar
• Drent ML, Jakobsdottir S, van Wijk JAE, Oostdijk W, Wit JM. Acceptability of liquid human growth hormone (hGH) [Norditropin Simple Xx®] in adults and children with GH deficiency and children with chronic renal disease. Clin Drug Investig. 2002;22(9):633–638. doi:10.2165/00044011-200222090-00008
   PubMed Web of Science ®Google Scholar
• Kappelgaard AM, Mikkelsen S, Bagger C, Fuchs GS. Children and adolescent acceptability of a new device system to administer human growth hormone–a pilot study. J Pediatr Endocrinol Metab. 2012;25(3–4):285–294. doi:10.1515/jpem-2011-0395
   PubMed Web of Science ®Google Scholar
• Fuchs GS, Mikkelsen S, Knudsen TK, Kappelgaard AM. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test. Clin Ther. 2009;31(12):2906–2914. doi:10.1016/j.clinthera.2009.12.014
   PubMed Web of Science ®Google Scholar
• Laursen T, Hansen B, Fisker S. Pain perception after subcutaneous injections of media containing different buffers. Basic Clin Pharmacol Toxicol. 2006;98(2):218–221. doi:10.1111/j.1742-7843.2006.pto_271.x
   PubMed Web of Science ®Google Scholar
• Iwanaga M, Kamoi K. Patient perceptions of injection pain and anxiety: a comparison of NovoFine 32-gauge tip 6mm and Micro Fine Plus 31-gauge 5mm needles. Diabetes Technol Ther. 2009;11(2):81–86. doi:10.1089/dia.2008.0027
   PubMed Web of Science ®Google Scholar
• Hokken-Koelega A, Keller A, Rakov V, Kipper S, Dahlgren J. Patient acceptance, ease of use, and preference for Norditropin NordiFlex with NordiFlex PenMate: results from an open-label, user survey of everyday use. ISRN Endocrinol. 2011;2011:803948. doi:10.5402/2011/803948
   PubMedGoogle Scholar
• Ranke MB, Lindberg A, Tanaka T, Camacho-Hübner C, Dunger DB, Geffner ME. Baseline characteristics and gender differences in prepubertal children treated with growth hormone in Europe, USA, and Japan: 25 years’ KIGS® experience (1987–2012) and review. Horm Res Paediatr. 2017;87(1):30–41. doi:10.1159/000452887
   Web of Science ®Google Scholar